Vera Reports Positive Data In Phase 2b ORIGIN Clinical Trial OLE In IgA Nephropathy; Stock Up
Vera Therapeutics, Inc. (VERA), a late clinical-stage biotechnology company focused on serious immunologic diseases, announced Thursday positive 72-week data from the open label extension or OLE period of its Phase 2b ORIGIN clinical trial of atacicept in participants with IgA nephropathy or IgAN.
Source: rttnews.com